Cover Image
市場調查報告書

神經調節設備的全球市場:各技術 (腦深部刺激,薦椎神經刺激,迷走神經刺激,脊椎刺激) 、各用途及生醫材料 - 市場機會分析及產業預測

Neuromodulation Devices Market by Technology (Deep Brain Stimulation, Sacral Nerve Stimulation, Vagus Nerve Stimulation, Spinal Cord Stimulation), Application and Biomaterial - Global Opportunity Analysis and Industry Forecast, 2014 - 2022

出版商 Allied Market Research 商品編碼 370270
出版日期 內容資訊 英文 127 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
神經調節設備的全球市場:各技術 (腦深部刺激,薦椎神經刺激,迷走神經刺激,脊椎刺激) 、各用途及生醫材料 - 市場機會分析及產業預測 Neuromodulation Devices Market by Technology (Deep Brain Stimulation, Sacral Nerve Stimulation, Vagus Nerve Stimulation, Spinal Cord Stimulation), Application and Biomaterial - Global Opportunity Analysis and Industry Forecast, 2014 - 2022
出版日期: 2016年08月01日 內容資訊: 英文 127 Pages
簡介

全球神經調節設備市場預測在2022年前將達到117億1,700萬美元的規模。神經刺激設備的安全性和有效性認知度的提升、疾病罹患率的上升,全球針對神經刺激領域的技術創新之臨床實驗數量的增加等,都推動了市場的成長。

本報告提供全球神經調節設備市場相關調查,彙整市場上各技術,各用途及生醫材料趨勢與各地區趨勢,2014∼2022年的預測,及加入此市場的主要企業簡介等資料。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 主要調查結果
  • 波特五力分析
  • 市場佔有率分析
  • 市場趨勢
    • 促進要素
    • 阻礙要素
    • 機會

第4章 各技術市場

  • 概要
  • 體內神經調節
  • 體外神經調節

第5章 各用途市場

  • 概要
    • 市場規模與預測
    • Failed back syndrome
    • 慢性疼痛
    • 癲癇
    • 原發性震顫
    • 尿失禁
    • 憂鬱
    • 肌張力不全症
    • 胃輕癱
    • 帕金森氏症
    • 偏頭痛
    • 強迫症

第6章 各材質市場

  • 概要
    • 市場規模與預測
    • 陶瓷生醫材料
    • 金屬製生醫材料
    • 聚合物生醫材料

第7章 各地區市場

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美·中東·非洲

第8章 企業簡介

  • ALEVA NEUROTHERAPEUTICS SA
  • BioControl Medical
  • Bioness Inc.
  • Boston Scientific Corporation
  • EnteroMedics Inc.
  • LivaNova PLC
  • Medtronic plc
  • NeuroPace, Inc.
  • Nevro Corporation
  • St. Jude Medical, Inc.

圖表

目錄
Product Code: LI 161489

Cover Image Neuromodulation Devices Market by Technology (Deep Brain Stimulation, Sacral Nerve Stimulation, Vagus Nerve Stimulation, Spinal Cord Stimulation), Application (Chronic Pain Management, Failed back syndrome, Epilepsy, Tremor, Incontinence, Depression, Dystonia, Gastroparesis, Parkinson's disease, Obsessive-Compulsive Disorder, Migraine) and Biomaterial (Metallic, Polymeric, Ceramic) - Global Opportunity Analysis and Industry Forecast, 2014 - 2022

No. of pages: 168, No. of Tables: 52, List of figures: 42, Category: Life Sciences, Sub Category: Medical Devices, Author: Deepa Tatkare, Price: $4,740

Neuromodulation is the alteration of nerve activity by delivering electrical impulses directly to a target area. Neurological disorders such as epilepsy, Alzheimer disease, cerebrovascular diseases, and Parkinson's disease affect the central and peripheral nervous system. Bacterial, viral, and fungal infections can also cause neurological disorders. Growth in the Neuromodulation devices market is attributed to increasing prevalence of neurological disorders due to rapidly rising geriatric population, increasing adoption of neuromodulation devices in developed countries, and growing focus of big players, such as Medtronic and Boston Scientific, on R&D in the segment.

The world neuromodulation devices market is estimated to reach $11,717 million by 2022. The market is expected to be driven by the increasing awareness about the safety and efficacy of neuromodulation devices, rising prevalence of neurological disorders and rising number of clinical trials worldwide for the development of innovative technologies in the field of neuromodulators. However, lack of trained healthcare professionals and stringent approval policies restrain the market growth.

The world neuromodulation devices market is segmented on the basis of product type, technology, application, material and geography. Based on product type, it is categorized into internal and external neuromodulation. Based on technology, Internal neuromodulation is segmented into five major segments, namely, deep brain stimulators, sacral nerve stimulators, spinal cord stimulators, vagus nerve stimulators and other neuromodulation devices. Similarly, based on technology external neuromodulation are classified into transcutaneous electrical nerve stimulation and repetitive transcranial magnetic stimulation. Spinal cord stimulators generated the highest revenue in 2015, whereas the deep brain stimulation market is expected to grow fastest by a CAGR of 13.9%. By application, the market is segmented into the following nine segments: failed back syndrome, chronic pain management, epilepsy, tremors, urinary and fecal incontinence, depression, dystonia, gastroparesis, Parkinson's disease, obsessive-compulsive disorder, migraine, depression and other applications. By biomaterial type, it is divided into metallic biomaterials, ceramic biomaterials and polymeric biomaterials.

Geographically, it is segmented into North America, Europe, Asia-Pacific and LAMEA. Presently, North America occupies the largest market share, followed by Europe and Asia-Pacific. Asia-Pacific is expected to witness maximum growth during the forecast period.

Key strategies adopted by major players include increasing focus on clinical trials for the development of innovative technologies, expanding the indications of the currently marketed neuromodulation devices and mergers &acquisitions. For instance, Boston Scientific is conducting clinical trials oftheir occipital nerve stimulator precision system for chronic migraine. In the year 2015, St. Jude Medical acquired Spinal Modulation Inc. for their AxiumNeurostimulator System.

The report provides comprehensive analyses of the key players operating in the neuromodulation devices market such as Medtronic plc, St. Jude Medical, Inc., LivaNova PLC, Boston Scientific Corporation, Aleva Neurotherapeutics SA, BioControl Medical, Bioness Inc., EnteroMedics Inc, Nevro Corporation and NeuroPace Inc.

Key Market Benefits

  • The study provides an in-depth analysis of the world neuromodulation devices market with current trends and future estimations to elucidate the imminent investment pockets.
  • The report provides a quantitative analysis from 2014 to 2022, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis by product helps in understanding the various types of devices used for the treatment of neurological diseases and other related conditions.
  • Competitive intelligence highlights the business practices followed by leading players across various regions.
  • SWOT analysis studies the internal environment of the leading companies for strategy formulation.

Key Market Segments

The world neuromodulation devices market is segmented based on technology, applications, material and geography.

By Technology

  • Internal neuromodulation
  • Deep Brain Stimulation
  • Sacral Nerve Stimulation
  • Vagus Nerve Stimulation
  • Spinal Cord Stimulation
  • Other Neuromodulation Technologies
  • External neuromodulation
  • Transcutaneous Electrical Nerve Stimulation
  • Transcranial Magnetic Stimulation

By Application

  • Chronic Pain Management
  • Failed back syndrome
  • Epilepsy
  • Tremor
  • Urinary and Fecal Incontinence
  • Depression
  • Dystonia
  • Gastroparesis
  • Parkinson's disease
  • Obsessive-Compulsive Disorder
  • Migraine
  • Other Applications

By Biomaterial

  • Metallic Biomaterials
  • Polymeric Biomaterials
  • Ceramic Biomaterials

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • South Korea
    • Malaysia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Israel
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

Table of Contents

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key benefits
  • 1.3. Research methodology
    • 1.3.1. Secondary research
    • 1.3.2. Primary research
    • 1.3.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top investment pockets
    • 3.2.2. Top winning strategies
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of new entrants
    • 3.3.4. Intensity of rivalry
    • 3.3.5. Threat of substitutes
  • 3.4. Market share analysis, 2015
  • 3.5. Market dynamics
    • 3.5.1. Drivers
      • 3.5.1.1. Ageing population and increasing incidence of neurological diseases
      • 3.5.1.2. Rise in the number of migraine and epilepsy patients and increase of neurostimulators in the treatment of depression and sleep apnea
      • 3.5.1.3. Increasing focus of leading companies in the neurostimulation segment
      • 3.5.1.4. New device approvals and increased clinical evidence of effectiveness
    • 3.5.2. Restraints
      • 3.5.2.1. Lack of skilled professionals
      • 3.5.2.2. High cost and lack of reimbursement
    • 3.5.3. Opportunities
      • 3.5.3.1. Rising healthcare expenditure in developing countries
      • 3.5.3.2. Use of neurostimulators for new indications
      • 3.5.3.3. Rising patient awareness about nuerostimulators

CHAPTER 4: WORLD NEUROMODULATION MARKET, BY TECHNOLOGY

  • 4.1. OVERVIEW
    • 4.1.1. Market size and forecast
  • 4.2. INTERNAL NEUROMODULATION
    • 4.2.1. Key market trends
    • 4.2.2. Key growth factors and opportunities
    • 4.2.3. Market size and forecast
    • 4.2.4. Deep brain stimulation
      • 4.2.4.1. Market size and forecast
    • 4.2.5. Sacral nerve stimulation
      • 4.2.5.1. Market size and forecast
    • 4.2.6. Spinal cord stimulation
      • 4.2.6.1. Market size and forecast
    • 4.2.7. Vagus nerve stimulation
      • 4.2.7.1. Market size and forecast
    • 4.2.8. Other neuromodulation
      • 4.2.8.1. Market size and forecast
  • 4.3. External Neuromodulation
    • 4.3.1. Key market trends
    • 4.3.2. Key growth factors and opportunities
    • 4.3.3. Market size and forecast
    • 4.3.4. Transcutaneous electrical nerve stimulation
      • 4.3.4.1. Market size and forecast
    • 4.3.5. Transcranial magnetic stimulation
      • 4.3.5.1. Market size and forecast

CHAPTER 5: WORLD NEUROMODULATION MARKET, BY APPLICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
    • 5.1.2. Failed back syndrome
      • 5.1.2.1. Market size and forecast
    • 5.1.3. Chronic pain
      • 5.1.3.1. Market size and forecast
    • 5.1.4. Epilepsy
      • 5.1.4.1. Market size and forecast
    • 5.1.5. Essential tremor
      • 5.1.5.1. Market size and forecast
    • 5.1.6. Urinary and fecal incontinence
      • 5.1.6.1. Market size and forecast
    • 5.1.7. Depression
      • 5.1.7.1. Market size and forecast
    • 5.1.8. Dystonia
      • 5.1.8.1. Market size and forecast
    • 5.1.9. Gastroparesis
      • 5.1.9.1. Market size and forecast
    • 5.1.10. Parkinson's disease
      • 5.1.10.1. Market size and forecast
    • 5.1.11. Migraine
      • 5.1.11.1. Market size and forecast
    • 5.1.12. Obsessive-compulsive disorder
      • 5.1.12.1. Market size and forecast
    • 5.1.13. Other applications
      • 5.1.13.1. Market size and forecast

CHAPTER 6: WORLD NEUROMODULATION MARKET, BY BIOMATERIAL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
    • 6.1.2. Ceramics biomaterials
      • 6.1.2.1. Market size and forecast
    • 6.1.3. Metallic biomaterials
      • 6.1.3.1. Market size and forecast
    • 6.1.4. Polymeric biomaterials
      • 6.1.4.1. Market size and forecast

CHAPTER 7: WORLD NEUROMODULATION MARKET, BY GEOGRAPHY

  • 7.1. Overview
    • 7.1.1. Market size and forecast
  • 7.2. North America
    • 7.2.1. Key market trends
    • 7.2.2. Key growth factors and opportunities
    • 7.2.1. Market size and forecast
      • 7.2.1.1. U.S. market size and forecast
      • 7.2.1.2. Canada market size and forecast
      • 7.2.1.3. Mexico market size and forecast
  • 7.3. Europe
    • 7.3.1. Key market trends
    • 7.3.2. Key growth factors and opportunities
    • 7.3.1. Market size and forecast
      • 7.3.1.1. Germany market size and forecast
      • 7.3.1.2. France market size and forecast
      • 7.3.1.3. U.K. market size and forecast
      • 7.3.1.4. Italy market size and forecast
      • 7.3.1.5. Spain market size and forecast
      • 7.3.1.6. Rest of europe market size and forecast
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends
    • 7.4.2. Key growth factors and opportunities
    • 7.4.1. Market size and forecast
      • 7.4.1.1. Japan market size and forecast
      • 7.4.1.2. China market size and forecast
      • 7.4.1.3. India market size and forecast
      • 7.4.1.4. South Korea market size and forecast
      • 7.4.1.5. Malaysia market size and forecast
      • 7.4.1.6. Rest of Asia-Pacific market size and forecast
  • 7.5. LAMEA
    • 7.5.1. Key market trends
    • 7.5.2. Key growth factors and opportunities
    • 7.5.1. Market size and forecast
      • 7.5.1.1. Brazil market size and forecast
      • 7.5.1.2. Israel market size and forecast
      • 7.5.1.3. Saudi Arabia market size and forecast
      • 7.5.1.4. South Africa market size and forecast
      • 7.5.1.5. Rest of LAMEA market size and forecast

CHAPTER 8: COMPANY PROFILES

  • 8.1. ALEVA NEUROTHERAPEUTICS SA
    • 8.1.1. Company overview
    • 8.1.2. Company snapshot
    • 8.1.3. Operating business segments
    • 8.1.4. Key strategic moves & developments
  • 8.2. BioControl Medical
    • 8.2.1. Company overview
    • 8.2.2. Company snapshot
    • 8.2.3. Operating business segments
    • 8.2.4. Key strategic moves & developments
  • 8.3. Bioness Inc.
    • 8.3.1. Company overview
    • 8.3.2. Company snapshot
    • 8.3.3. Operating business segments
    • 8.3.4. Key strategic moves & developments
  • 8.4. Boston Scientific Corporation
    • 8.4.1. Company overview
    • 8.4.2. Company snapshot
    • 8.4.3. Operating business segments
    • 8.4.4. Business performance
    • 8.4.5. Key strategic moves & developments
  • 8.5. EnteroMedics Inc.
    • 8.5.1. Company overview
    • 8.5.2. Company snapshot
    • 8.5.3. Operating business segments
    • 8.5.4. Business performance
    • 8.5.5. Key strategic moves & developments
  • 8.6. LivaNova PLC
    • 8.6.1. Company overview
    • 8.6.2. Company snapshot
    • 8.6.3. Operating business segments
    • 8.6.4. Business performance
    • 8.6.5. Key strategic moves & developments
  • 8.7. Medtronic plc
    • 8.7.1. Company overview
    • 8.7.2. Company snapshot
    • 8.7.3. Operating business segments
    • 8.7.4. Business performance
    • 8.7.5. Key strategic moves & developments
  • 8.8. NeuroPace, Inc.
    • 8.8.1. Company overview
    • 8.8.2. Company snapshot
    • 8.8.3. Operating business segments
    • 8.8.4. Key strategic moves & developments
  • 8.9. Nevro Corporation
    • 8.9.1. Company overview
    • 8.9.2. Company snapshot
    • 8.9.3. Operating business segments
    • 8.9.4. Business performance
    • 8.9.5. Key strategic moves & developments
  • 8.10. St. Jude Medical, Inc.
    • 8.10.1. Company overview
    • 8.10.2. Company snapshot
    • 8.10.3. Operating business segments
    • 8.10.4. Business performance
    • 8.10.5. Key strategic moves & developments

List of Tables

  • TABLE 1: WORLD NEUROMODULATION MARKET, BY TECHNOLOGY, 2014-2022 ($MILLION)
  • TABLE 2: INTERNAL NEUROMODULATION MARKET, BY TECHNOLOGY, 2014-2022 ($MILLION)
  • TABLE 3: EXTERNAL NEUROMODULATION MARKET, BY TECHNOLOGY, 2014-2022 ($MILLION)
  • TABLE 4: WORLD NEUROMODULATION MARKET, BY APPLICATION, 2014-2022 ($MILLION)
  • TABLE 5: NEUROMODULATION MARKET FOR FAILED BACK SYNDROME, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 6: NEUROMODULATION MARKET FOR CHRONIC PAIN, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 7: NEUROMODULATION MARKET FOR EPILEPSY, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 8: NEUROMODULATION MARKET FOR ESSENTIAL TREMOR, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 9: NEUROMODULATION MARKET FOR URINARY AND FECAL INCONTINENCE, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 10: NEUROMODULATION MARKET FOR DEPRESSION, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 11: NEUROMODULATION MARKET FOR DYSTONIA, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 12: NEUROMODULATION MARKET FOR GASTROPARESIS, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 13: NEUROMODULATION MARKET FOR PARKINSON'S DISEASE, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 14: NEUROMODULATION MARKET FOR MIGRAINE, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 15: NEUROMODULATION MARKET FOR OBSESSIVE-COMPULSIVE DISORDER, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 16: NEUROMODULATION MARKET FOR OTHER APPLICATIONS, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 17: WORLD NEUROMODULATION MARKET, BY BIOMATERIAL, 2014-2022 ($MILLION)
  • TABLE 18: NEUROMODULATION MARKET FOR CERAMIC BIOMATERIALS, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 19: NEUROMODULATION MARKET FOR METALLIC BIOMATERIALS, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 20: NEUROMODULATION MARKET FOR POLYMERIC BIOMATERIALS, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 21: NEUROMODULATION MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 22: NORTH AMERICA NEUROMODULATION MARKET, BY COUNTRY, 2014-2022 ($MILLION)
  • TABLE 23: NORTH AMERICA NEUROMODULATION MARKET, BY APPLICATION, 2014-2022 ($MILLION)
  • TABLE 24: NORTH AMERICA NEUROMODULATION MARKET, BY BIOMATERIAL, 2014-2022 ($MILLION)
  • TABLE 25: EUROPE NEUROMODULATION MARKET, BY COUNTRY, 2014-2022 ($MILLION)
  • TABLE 26: EUROPE NEUROMODULATION MARKET, BY APPLICATION, 2014-2022 ($MILLION)
  • TABLE 27: EUROPE NEUROMODULATION MARKET, BY BIOMATERIAL, 2014-2022 ($MILLION)
  • TABLE 28: ASIA-PACIFIC NEUROMODULATION MARKET, BY COUNTRY, 2014-2022 ($MILLION)
  • TABLE 29: ASIA-PACIFIC NEUROMODULATION MARKET, BY APPLICATION, 2014-2022 ($MILLION)
  • TABLE 30: ASIA-PACIFIC NEUROMODULATION MARKET, BY BIOMATERIAL, 2014-2022 ($MILLION)
  • TABLE 31: LAMEA NEUROMODULATION MARKET, BY COUNTRY, 2014-2022 ($MILLION)
  • TABLE 32: LAMEA NEUROMODULATION MARKET, BY APPLICATION, 2014-2022 ($MILLION)
  • TABLE 33: LAMEA NEUROMODULATION MARKET, BY BIOMATERIAL, 2014-2022 ($MILLION)
  • TABLE 34: ALEVA: COMPANY SNAPSHOT
  • TABLE 35: ALEVA: PRODUCT CATEGORIES
  • TABLE 36: BIOCONTROL MEDICAL: COMPANY SNAPSHOT
  • TABLE 37: BIOCONTRL MEDICAL: PRODUCT CATEGORIES
  • TABLE 38: BIONESS: COMPANY SNAPSHOT
  • TABLE 39: BIONESS: PRODUCT CATEGORIES
  • TABLE 40: BOSTON SCIENTIFIC: COMPANY SNAPSHOT
  • TABLE 41: BOSTON SCIENTIFIC: PRODUCT CATEGORIES
  • TABLE 42: ENTEROMEDICSINC: COMPANY SNAPSHOT
  • TABLE 43: ENTEROMEDICSINC: PRODUCT CATEGORIES
  • TABLE 44: LIVANOVA: COMPANY SNAPSHOT
  • TABLE 45: LIVANOVA: PRODUCT CATEGORIES
  • TABLE 46: MEDTRONIC: COMPANY SNAPSHOT
  • TABLE 47: MEDTRONIC: OPERATING SEGMENTS
  • TABLE 48: NEUROPACE: COMPANY SNAPSHOT
  • TABLE 49: NEVRO: COMPANY SNAPSHOT
  • TABLE 50: NEVRO: PRODUCT CATEGORIES
  • TABLE 51: ST. JUDE MEDICAL: COMPANY SNAPSHOT
  • TABLE 52: ST. JUDE MEDICAL: PRODUCT CATEGORIES

List of Figures

  • FIG. 1: TOP INVESTMENT POCKETS IN WORLD NEUROMODULATION MARKET
  • FIG. 2: TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, (2014-2016)
  • FIG. 3: TOP WINNING STRATEGIES: NATURE AND TYPE
  • FIG. 4: PORTER'S FIVE FORCES ANALYSIS
  • FIG. 5: MARKET SHARE ANALYSIS, 2015
  • FIG. 6: U.S. NEUROMODULATION MARKET, 2014-2022 ($MILLION)
  • FIG. 7: CANADA NEUROMODULATION MARKET, 2014-2022 ($MILLION)
  • FIG. 8: MEXICO NEUROMODULATION MARKET, 2014-2022 ($MILLION)
  • FIG. 9: GERMANY NEUROMODULATION MARKET, 2014-2022 ($MILLION)
  • FIG. 10: FRANCE NEUROMODULATION MARKET, 2014-2022 ($MILLION)
  • FIG. 11: U.K. NEUROMODULATION MARKET, 2014-2022 ($MILLION)
  • FIG. 12: ITALY NEUROMODULATION MARKET, 2014-2022 ($MILLION)
  • FIG. 13: SPAIN NEUROMODULATION MARKET, 2014-2022 ($MILLION)
  • FIG. 14: REST OF EUROPE NEUROMODULATION MARKET, 2014-2022 ($MILLION)
  • FIG. 15: JAPAN NEUROMODULATION MARKET, 2014-2022 ($MILLION)
  • FIG. 16: CHINA NEUROMODULATION MARKET, 2014-2022 ($MILLION)
  • FIG. 17: INDIA NEUROMODULATION MARKET, 2014-2022 ($MILLION)
  • FIG. 18: SOUTH KOREA NEUROMODULATION MARKET, 2014-2022 ($MILLION)
  • FIG. 19: MALAYSIA NEUROMODULATION MARKET, 2014-2022 ($MILLION)
  • FIG. 20: REST OF ASIA-PACIFIC NEUROMODULATION MARKET, 2014-2022 ($MILLION)
  • FIG. 21: BRAZIL NEUROMODULATION MARKET, 2014-2022 ($MILLION)
  • FIG. 22: ISRAEL NEUROMODULATION MARKET, 2014-2022 ($MILLION)
  • FIG. 23: SAUDI ARABIA NEUROMODULATION MARKET, 2014-2022 ($MILLION)
  • FIG. 24: SOUTH AFRICA NEUROMODULATION MARKET, 2014-2022 ($MILLION)
  • FIG. 25: REST OF LAMEA NEUROMODULATION MARKET, 2014-2022 ($MILLION)
  • FIG. 26: BOSTON SCIENTIFIC: REVENUE, 2013-2015 ($MILLION)
  • FIG. 27: BOSTON SCIENTIFIC: REVENUE, BY BUSINESS SEGMENT, 2015 (%)
  • FIG. 28: BOSTON SCIENTIFIC: REVENUE, BY SUB SEGMENT, 2015 (%)
  • FIG. 29: BOSTON SCIENTIFIC: REVENUE, BY GEOGRAPHY, 2015 (%)
  • FIG. 30: LIVANOVA: REVENUE, 2013-2015 ($MILLION)
  • FIG. 31: LIVANOVA: REVENUE, BY BUSINESS SEGMENT, 2015 (%)
  • FIG. 32: LIVANOVA: REVENUE, BY GEOGRAPHY, 2015 (%)
  • FIG. 33: LIVANOVA: REVENUE, BY GEOGRAPHY, 2015 (%)
  • FIG. 34: MEDTRONIC: REVENUE, 2014-2016 ($MILLION)
  • FIG. 35: MEDTRONIC: REVENUE, BY SEGMENT, 2016 (%)
  • FIG. 36: MEDTRONIC: CARDIAC AND VASCULAR GROUP REVENUE, BY SUBSEGMENT, 2016 (%)
  • FIG. 37: MEDTRONIC: REVENUE, BY GEOGRAPHY, 2016 (%)
  • FIG. 38: NEVRO: REVENUE, 2013-2015 ($MILLION)
  • FIG. 39: NEVRO: REVENUE BY GEOGRAPHY, 2015 (%)
  • FIG. 40: ST. JUDE MEDICAL: REVENUE, 2013-2015 ($MILLION)
  • FIG. 41: ST. JUDE MEDICAL: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
  • FIG. 42: ST. JUDE MEDICAL: REVENUE, BY GEOGRAPHY, 2015 (%)
Back to Top